Research with human participants

Overview of medical research in the Netherlands

The effect of Alphabodies® against human lnterleukin lL23 in the transplant model of psoriasis, in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intradermally into the transplant.

Published:
Last updated:

Are Alphabodies against IL23 effecive in the transplant model of psoriasis

Download: PDF | XML
Ethical review
Approved WMO
Status
Recruitment stopped
Health condition type
Other condition
Study type
Observational invasive

ID

NL-OMON39832

Source

ToetsingOnline

Brief title

The effect of Alphabodies® against lnterleukin lL23 in the psoriasis model

Condition

  • Other condition
  • Autoimmune disorders
  • Epidermal and dermal conditions

Synonym

Psoriasis

Health condition

een onderzoek naar werking van een middel in een model.

Research involving

Human

Sponsors and support

Primary sponsor :
Complix
Source(s) of monetary or material Support :
Industry

Intervention

Keyword :
psoriasis, skin, therapies, transplant

Outcome measures

Primary outcome

NVT

Secondary outcome

NVT

Background summary

Complix wishes to know if Alphabodies are effecive in the transplant model of
psoriasis

Study objective

Are Alphabodies against IL23 effecive in the transplant model of psoriasis

Study design

Blood and skin biopsies are taken from patients with psoriasis vungaris

Study burden and risks

NVT

Public
Complix

Technologiepark 4
Gent 9051
BE
Scientific
Complix

Technologiepark 4
Gent 9051
BE

Listed location countries

Netherlands

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients with light to mild psoriasis vulgaris.

Exclusion criteria

Volunteers cannot be treated systemically (for psoriasis)
Volunteers cannot have UV/light therapy
Volunteers cannot be taking immune-modulating drugs for other diseases
Volunteers should not have problems with the Köbner phenomenom.

Design

Study type :
Observational invasive
Masking :
Open (masking not used)
Control :
Uncontrolled
Primary purpose :
Other

Recruitment

NL
Recruitment status
:
Recruitment stopped
Start date (anticipated) :
Enrollment :
19
Type :
Anticipated

Approved WMO
Date :
Application type :
First submission
Review commission :
METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID
CCMO NL42848.098.12